Bristol-Myers Squibb Co. (BMY)

• Annual Data
• Quarterly Data

Bristol-Myers Squibb Co., Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity

		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014		Dec 31, 2013
	Short-term debt obligations
	Accounts payable
	Accrued rebates and returns
	Employee compensation and benefits
	Research and development
	Dividends
	Royalties
	Branded Prescription Drug Fee
	Restructuring
	Pension and postretirement benefits
	Litigation and other settlements
	Other
	Accrued liabilities
	Deferred income
	Income taxes payable
	Liabilities related to assets held-for-sale
	Current liabilities
	Deferred income
	Income taxes payable
	Pension and other liabilities
	Long-term debt, excluding current portion
	Non-current liabilities
	Total liabilities
	Preferred stock, $2 convertible series, par value $1 per share
	Common stock, par value of $0.10 per share
	Capital in excess of par value of stock
	Accumulated other comprehensive loss
	Retained earnings
	Cost of treasury stock
	Total Bristol-Myers Squibb Company shareholders’ equity
	Noncontrolling interest
	Total equity
	Total liabilities and equity

Based on: 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13), 10-K (filing date: 2014-02-14).